Selvita Opens New Research Site in Poznan
News Feb 05, 2016
Selvita has signed a contract for the lease of laboratory space in Poznan, Poland. The new site will be located at in the Wielkopolska Centre of Advanced Technologies and commence research activities in the summer of 2016.
The initial laboratory space will amount to 5,500 sq. feet, which constitutes nearly 20% increase in Selvita laboratory space, compared to the current state with significant extension possibilities.
Poznan facility will be the first Selvita research site outside Krakow and its opening will fulfill one of the strategic goals presented during Selvita’s IPO in December 2014.
At the beginning, Selvita plans to employ approx. 50 people in Poznan - mostly chemists and biologists - gradually increasing their number in subsequent periods. Ultimately, the facility in Poznan is meant to be the "second heart of Selvita", providing both contract services, as well as actively participating in internal R&D projects.
“Wielkopolska region has a fantastic scientific potential. We are fully aware that for many talented graduates from local universities, the decision to relocate to Krakow can be very difficult, and for this reason we decided to come to them,” says Dr. Miroslawa Zydron, Director of the Contract Chemistry Department and Member of the Management Board at Selvita.
“The foundation of Poznan team will be the employees coming from that region, who have already been working at Selvita for some time, in our laboratories in Krakow. Recently we have been also recruiting locally in Poznan. Selected candidates are being invited to join Selvita for a few months in Krakow, so they can have the opportunity to get to know our company and its organization, before they start working in Poznan,” she added.
Selvita headquarters and the main laboratories with a research space of 30,000 sq. foot, are located in Krakow, Poland. In 2015, Selvita opened its subsidiaries in major biotech centers in the world – Selvita Inc. in the Greater Boston Area, in the San Francisco Bay Area in US and Selvita Ltd. in Cambridge, UK.
Kidney Cancer Driver Could Lead to New Treatment StrategyNews
Scientists have uncovered a potential therapeutic target for kidney cancers that have a common genetic change. Scientists have known this genetic change can lead to an overabundance of blood vessels, which help feed nutrients to the tumors. Their latest finding shows a potential new cancer-driving pathway.READ MORE
Targeting Headaches and Tumors with Nano-SubmarinesNews
Scientists have developed a new method to enable miniature drug-filled nanocarriers to dock on to immune cells, which in turn attack tumors. In the future, this may lead to targeted treatment that can largely eliminate damage to healthy tissue.READ MORE
CRISPR Screening Reveals Sickle Cell Disease TargetNews
A key signaling protein, known as heme-regulated inhibitor (HRI), has been identified as a potential therapeutic target for the development of drugs to treat sickle cell disease, using a CRISPR screening approach.READ MORE